SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on November 7, 2013, covering events occurring on November 6, 2013. The registrant is a Delaware corporation headquartered in San Diego, California.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of corporate events rather than a financial statement.
Material Changes
No material financial changes or comparative period data are disclosed in this filing. The report focuses on regulatory disclosures and corporate communications.
Guidance, Outlook, and Events
- Regulation FD Disclosure (Item 7.01): The Company attached a presentation (Exhibit 99.1) used by management in meetings to describe the Company. This information is not deemed "filed" for purposes of the Exchange Act.
- Other Events (Item 8.01): The Company issued a press release on November 6, 2013, which is included as Exhibit 99.2.
- Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the standard disclaimer regarding the non-filed status of the attached presentation.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (Presentation) and Exhibit 99.2 (Press Release) for specific business updates, as the 8-K body only references them.
- Note that the presentation materials are not incorporated by reference into the filing unless specifically cited in future documents.
- Confirm the company name is Imprimis Pharmaceuticals, Inc., as the metadata request incorrectly referenced "Harrow, Inc."